News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

responsif GmbH Release: Cancer Researchers At An University In Stockholm, Sweden, And Biotechnology Experts In Erlangen, Germany, Join Forces To Fight Cancer


10/19/2005 5:10:28 PM

The German biotechnology company responsif GmbH and scientists from a prestigious University in Stockholm, Sweden have recently signed a Cooperation Agreement which will bring a promising new treatment for cancer one step closer to clinical trials. The Swedish cancer researchers working in the Dept. of Oncology & Pathology in the Section for Experimental Oncology are now using an “anchoring” technique developed by responsif to pack tumour antigens into virus capsoids; the aim is to create an anti-tumour vaccine which will mobilise the body’s own immune defences against cancer cells.


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES